ArticleBMC cancer2026
A mechanistic study revealing that SLCO1B3 promotes gastric cancer development and metastasis through MAP1S expression downregulation.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGastric cancer (GC) remains a significant cause of mortality worldwide. Exploring the pathogenesis of GC is crucial for developing new therapeutic strategies.
methodsClinical sample sequencing and immunohistochemical analyses were employed to investigate the expression patterns of solute carrier organic anion transporter B3 (SLCO1B3) in GC and surrounding normal tissues, as well as its effect on GC prognosis. In vitro GC studies were performed to confirm the effects of SLCO1B3 overexpression and knockdown on GC cell proliferation, migration, and invasion, as well as the influence of SLCO1B3 overexpression on carcinogenesis in vivo. Furthermore, RNA sequencing of gastric cancer cells overexpressing SLCO1B3 revealed microtubule-associated protein 1 S (MAP1S) as a potential downstream target, suggesting SLCO1B3 may promote gastric cancer progression by regulating MAP1S expression.
conclusionSLCO1B3 expression is elevated in GC versus adjacent tissues and correlates with diminished patient survival rates. Overexpression of Ct-SLCO1B3 may be associated with downregulation of MAP1S, suggesting that Ct-SLCO1B3 may promote gastric cancer development and metastasis by regulating its expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.